CTIS2022-500210-26-00招募中1 期
HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1) ADPKD diagnosis (modified Ravine criteria) 2 =18 years old 3) eGFR > 25 mL/min/1.73m2 (in Belgium eGFR > 35 mL/min/1.73m2) 4) On stable treatment with the highest tolerated dose of V2RA for a minimum of 3 months
排除标准
- •1) Known intolerance to hydrochlorothiazide 2) Use of any diuretic 3) Changes in antihypertensive treatment in the last month 4) Orthostatic hypotension or blood pressure < 105/65 mmHg 5) Uncontrolled hypertension (blood pressure >160/100mmHg) 6) Hypokalemia (<3.5 mmol/L) 7) Diabetes mellitus type 1 or type 2 8) Primary renal disease other than ADPKD 9) History of active gout despite maintenance preventive treatment for gout (allopurinol, desuric, febuxostat and/or colchicine), defined as =2 episodes during the last year 10) History of skin cancer (basal cell, squamous cell and melanoma) 11) Anuria 12) Severe liver function impairment 13) Hypercalcemia 14) Salt losing nephropathy 15) Pregnancy 16) Breast feeding 17) Concurrent use of any medications listed under 8.1.2 18) Not able to give informed consent
研究者
相似试验
招募中
3 期
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of LifeADPKDNCT05373264University Medical Center Groningen300
招募中
3 期
Efficacy of hydrochlorothiazide at renal pelvis stone free time after extra corporeal shock wake lithotripsy (ESWL)Stone in kidney.Calculus of kidneyIRCT20171104037212N2Rafsanjan University of Medical Sciences278
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-CZDAIICHI SANKYO EUROPE GmbH2,220
进行中（未招募）
1 期
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEficacia y seguridad de Hidroclorotiazida, utilizada como terapia adicional, en pacientes con hipertensión moderada a severa no controlados adecuadamente con Olmesartan MEdoxomil 40 mg en monoterapiaEssential hypertensionHipertensión esencialMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-ESDAIICHI SANKYO EUROPE GmbH1,500
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-DEDAIICHI SANKYO EUROPE GmbH1,500